Gut Microbiota, PGx and INSTIs Response

Last updated: May 8, 2024
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Overall Status: Completed

Phase

N/A

Condition

Hiv Infections

Treatment

Dolutegravir

Bictegravir

Clinical Study ID

NCT04805944
INSTI
  • Ages > 18
  • All Genders

Study Summary

This is an interventional phase IV trial enrolling HIV-infected patients treated by dolutegravir or bictegravir-based combined antiretroviral therapy, and patients with a planned shift to a dolutegravir or bictegravir-based combined antiretroviral therapy, that aims at understanding the individual response to dolutegravir and bictegravir, in terms of efficacy and toxicity.

Eligibility Criteria

Inclusion

Inclusion will be proposed to:

  • HIV infected adult patient regularly followed at Centre de reference HIV of CUSL andcurrently treated by 50mg OD of DTG (n=80) or 50mg OD of BIC (n=30).
  • Virally controlled immunologically functional HIV infected adult patient regularlyfollowed at Centre de reference HIV of CUSL and shifting from another ARV class to atreatment containing 50mg OD of DTG (n=20) or 50mg OD of BIC (n=20).
  • HIV infected adult patient retrospectively identified as having stopped standarddosage of DTG (ie. 50mg OD) due to NPAE (insomnia, depression, anxiety) (n=50).Identification will be based on the interrogation of our prospective clinicaldatabase.

Exclusion

Exclusion Criteria:

  • Pregnancy at the time of inclusion or expected pregnancy within 12 months, forpatients treated by DTG or BIC during the study
  • Liver failure (Child-Pugh A, B or C)

Study Design

Total Participants: 180
Treatment Group(s): 2
Primary Treatment: Dolutegravir
Phase:
Study Start date:
March 10, 2021
Estimated Completion Date:
December 31, 2023

Study Description

The main objective of our research project is to better define the inter-individual variability in terms of clinical and biological response towards Integrase Strand Transfer Inhibitors, an important ARV drug class used in the treatment of HIV infection. We aim at identifying predictors of drug efficacy and toxicity, which are eagerly awaited by clinicians as INSTIs are now prescribed worldwide and concerns about previously unidentified side effects are emerging.

The specific objectives of the project are:

  • To study the impact of genetic polymorphisms in selected pharmacogenes (including genes coding for biotransformation enzymes and transport proteins) on INSTIs PK parameters and biomarkers relevant for TDM, such as trough (C0) and intracellular (IC) concentrations.

  • To determine whether genetic polymorphisms in selected pharmacogenes might affect INSTIs efficacy, as assessed by the measurement of the viral load.

  • To address the important question of the pathophysiological mechanisms lying behind the two main side effects of INSTIs, namely neuropsychiatric adverse events and abnormal weight gain.

  • To describe how INSTIs affect the gut microbiome of treated patients, and to determine in turn how and by which pathways the gut microbiome might influence the clinical response (i.e. efficacy and toxicity) to INSTIs.

Connect with a study center

  • Cliniques universitaires Saint-Luc

    Brussels,
    Belgium

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.